Difference between revisions of "Desmoid tumor"
Jump to navigation
Jump to search
m |
|||
Line 13: | Line 13: | ||
=All lines of therapy= | =All lines of therapy= | ||
==Imatinib monotherapy {{#subobject:hg35dc|Regimen=1}}== | ==Imatinib monotherapy {{#subobject:hg35dc|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen variant #1, fixed dose {{#subobject:1jv5c2|Variant=1}}=== | ===Regimen variant #1, fixed dose {{#subobject:1jv5c2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 25: | Line 25: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Imatinib (Gleevec)]] 800 mg PO once per day | *[[Imatinib (Gleevec)]] 800 mg PO once per day | ||
− | |||
'''2 years of therapy''' | '''2 years of therapy''' | ||
− | + | </div></div><br> | |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen variant #2, BSA-based dosing {{#subobject:ugu9ac|Variant=1}}=== | ===Regimen variant #2, BSA-based dosing {{#subobject:ugu9ac|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 41: | Line 42: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Imatinib (Gleevec)]] by the following criteria: | *[[Imatinib (Gleevec)]] by the following criteria: | ||
Line 46: | Line 48: | ||
**BSA between 1 and 1.49 m<sup>2</sup>: 200 mg PO twice per day | **BSA between 1 and 1.49 m<sup>2</sup>: 200 mg PO twice per day | ||
**BSA less than 1 m<sup>2</sup>: 100 mg PO twice per day | **BSA less than 1 m<sup>2</sup>: 100 mg PO twice per day | ||
− | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
#Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010 Oct 1;16(19):4884-91. Epub 2010 Aug 19. [https://doi.org/10.1158/1078-0432.ccr-10-1177 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20724445/ PubMed] | #Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010 Oct 1;16(19):4884-91. Epub 2010 Aug 19. [https://doi.org/10.1158/1078-0432.ccr-10-1177 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20724445/ PubMed] | ||
#'''GISG-01:''' Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017 May;76:60-67. Epub 2017 Mar 8. [https://doi.org/10.1016/j.ejca.2017.02.001 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28282612/ PubMed] NCT01137916 | #'''GISG-01:''' Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017 May;76:60-67. Epub 2017 Mar 8. [https://doi.org/10.1016/j.ejca.2017.02.001 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28282612/ PubMed] NCT01137916 | ||
− | |||
==Methotrexate & Vinblastine {{#subobject:f3a6dz|Regimen=1}}== | ==Methotrexate & Vinblastine {{#subobject:f3a6dz|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:jgc1q1|Variant=1}}=== | ===Regimen {{#subobject:jgc1q1|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 71: | Line 71: | ||
|} | |} | ||
''Note: DESMOPAZ was randomized but non-comparative.'' | ''Note: DESMOPAZ was randomized but non-comparative.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Methotrexate (MTX)]] 30 mg/m<sup>2</sup> IV once on day 1 | *[[Methotrexate (MTX)]] 30 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Vinblastine (Velban)]] 5 mg/m<sup>2</sup> IV once on day 1 | *[[Vinblastine (Velban)]] 5 mg/m<sup>2</sup> IV once on day 1 | ||
− | |||
'''7-day cycle for 26 cycles, then 14-day cycle for 13 cycles''' | '''7-day cycle for 26 cycles, then 14-day cycle for 13 cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''POG 9650:''' Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10;25(5):501-6. [https://doi.org/10.1200/jco.2006.08.2966 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17290057/ PubMed] | #'''POG 9650:''' Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10;25(5):501-6. [https://doi.org/10.1200/jco.2006.08.2966 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17290057/ PubMed] | ||
#'''DESMOPAZ:''' Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. [https://doi.org/10.1016/s1470-2045(19)30276-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31331699/ PubMed] NCT01876082 | #'''DESMOPAZ:''' Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. [https://doi.org/10.1016/s1470-2045(19)30276-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31331699/ PubMed] NCT01876082 | ||
− | |||
==Pazopanib monotherapy {{#subobject:f3agdc|Regimen=1}}== | ==Pazopanib monotherapy {{#subobject:f3agdc|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:0gc1c2|Variant=1}}=== | ===Regimen {{#subobject:0gc1c2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 94: | Line 94: | ||
|} | |} | ||
''Note: this study was randomized but non-comparative.'' | ''Note: this study was randomized but non-comparative.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pazopanib (Votrient)]] 800 mg PO once per day | *[[Pazopanib (Votrient)]] 800 mg PO once per day | ||
− | |||
'''Up to 12 months of therapy''' | '''Up to 12 months of therapy''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''DESMOPAZ:''' Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. [https://doi.org/10.1016/s1470-2045(19)30276-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31331699/ PubMed] NCT01876082 | #'''DESMOPAZ:''' Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. [https://doi.org/10.1016/s1470-2045(19)30276-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31331699/ PubMed] NCT01876082 | ||
− | |||
==Pegylated liposomal doxorubicin monotherapy {{#subobject:cd6479|Regimen=1}}== | ==Pegylated liposomal doxorubicin monotherapy {{#subobject:cd6479|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:3cc773|Variant=1}}=== | ===Regimen {{#subobject:3cc773|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 114: | Line 114: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | *[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
#'''Case series:''' Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4. Epub 2009 Sep 18. [https://doi.org/10.1016/j.ejca.2009.08.016 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19767198/ PubMed] | #'''Case series:''' Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4. Epub 2009 Sep 18. [https://doi.org/10.1016/j.ejca.2009.08.016 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19767198/ PubMed] | ||
− | |||
==Sorafenib monotherapy {{#subobject:f3a4c7|Regimen=1}}== | ==Sorafenib monotherapy {{#subobject:f3a4c7|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:0dc9c2|Variant=1}}=== | ===Regimen {{#subobject:0dc9c2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
Line 138: | Line 138: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Sorafenib (Nexavar)]] 400 mg PO once per day | *[[Sorafenib (Nexavar)]] 400 mg PO once per day | ||
− | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
# '''Alliance A091105:''' Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20;379(25):2417-2428. [https://doi.org/10.1056/NEJMoa1805052 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6447029/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30575484 PubMed] NCT02066181 | # '''Alliance A091105:''' Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20;379(25):2417-2428. [https://doi.org/10.1056/NEJMoa1805052 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6447029/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30575484 PubMed] NCT02066181 | ||
− | |||
[[Category:Desmoid tumor regimens]] | [[Category:Desmoid tumor regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] |
Revision as of 17:33, 28 February 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens. For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
5 regimens on this page
7 variants on this page
|
All lines of therapy
Imatinib monotherapy
Regimen variant #1, fixed dose
Study | Years of enrollment | Evidence |
---|---|---|
Kasper et al. 2017 (GISG-01) | 2010-2013 | Phase 2 |
Regimen variant #2, BSA-based dosing
Study | Years of enrollment | Evidence |
---|---|---|
Chugh et al. 2010 | 2002-2005 | Phase 2 |
Targeted therapy
- Imatinib (Gleevec) by the following criteria:
- BSA of 1.5 m2 or more: 300 mg PO twice per day
- BSA between 1 and 1.49 m2: 200 mg PO twice per day
- BSA less than 1 m2: 100 mg PO twice per day
Continued indefinitely
References
- Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010 Oct 1;16(19):4884-91. Epub 2010 Aug 19. link to original article contains dosing details in manuscript PubMed
- GISG-01: Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017 May;76:60-67. Epub 2017 Mar 8. link to original article contains dosing details in manuscript PubMed NCT01137916
Methotrexate & Vinblastine
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Skapek et al. 2007 (POG 9650) | 1997-2001 | Phase 2 |
Toulmonde et al. 2019 (DESMOPAZ) | 2012-2017 | Randomized Phase 2 |
Note: DESMOPAZ was randomized but non-comparative.
Chemotherapy
- Methotrexate (MTX) 30 mg/m2 IV once on day 1
- Vinblastine (Velban) 5 mg/m2 IV once on day 1
7-day cycle for 26 cycles, then 14-day cycle for 13 cycles
References
- POG 9650: Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10;25(5):501-6. link to original article contains dosing details in manuscript PubMed
- DESMOPAZ: Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. link to original article contains dosing details in abstract PubMed NCT01876082
Pazopanib monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Toulmonde et al. 2019 (DESMOPAZ) | 2012-2017 | Randomized Phase 2 |
Note: this study was randomized but non-comparative.
References
- DESMOPAZ: Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. link to original article contains dosing details in abstract PubMed NCT01876082
Pegylated liposomal doxorubicin monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Constantinidou et al. 2009 | 2006-2009 | Case series |
Chemotherapy
- Pegylated liposomal doxorubicin (Doxil) 50 mg/m2 IV over 60 minutes once on day 1
28-day cycles
References
- Case series: Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4. Epub 2009 Sep 18. link to original article PubMed
Sorafenib monotherapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Gounder et al. 2018 (Alliance A091105) | 2014-2016 | Phase 3 (E-esc) | Placebo | Superior PFS PFS24: 81% vs 36% (HR 0.13, 95% CI 0.05-0.31) |
References
- Alliance A091105: Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20;379(25):2417-2428. link to original article contains dosing details in abstract link to PMC article PubMed NCT02066181